EndoPredict® at SABCS – Prospective long-term and real-world data Two prospective real-world studies presented at SABCS show EndoPredict® accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th Decemb... Read More
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con... Read More
EndoPredict informs treatment decisions for premenopausal breast cancer New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ... Read More
High adherence to EndoPredict test results in extended endocrine therapy decision making in early breast cancer Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and ... Read More